The QualityStocks Daily Friday, April 26th, 2024

Today's Top 3 Investment Newsletters

QualityStocks(KPLT) $12.7600 +35.74%

ChineseWire(IFBD) $4.9000 +32.79%

Schaeffer's(TPC) $17.7800 +28.01%

The QualityStocks Daily Stock List

Net Savings Link (NSAV)

QualityStocks, Investor Development Group, MarketClub Analysis, Real Pennies, TheMicrocapNews, Stockgoodies, SmallCapVoice and PennyTrader Publisher reported earlier on Net Savings Link (NSAV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Net Savings Link Inc. (OTC: NSAV) is an integrated technology firm that offers turnkey technological solutions to the legal medical marijuana and hemp industries as well as other areas of the medical industry.

The firm provides its services in the United States and has its headquarters in Cresco, Pennsylvania. Net Savings Link Inc. was established on February 21, 2007.

Net Savings Link Inc. operates through the Global Distribution Corporation, which is a subsidiary it owns. Through it, the firm markets and distributes natural remedies, wellness and supplement products. The firm also offers health and wellness products, including probiotics, mineral and vitamin supplements as well as other nutraceuticals health supplements, under its Nutra Horizon brand name.

Net Savings Link Inc. is also focused on providing various services which include e-commerce and software solutions. Additionally, it provides information technology, patents and trademarks, advisory services and financial services, among others. Net Savings Link Inc. also provides hemp based beer under the brand names Angry Tiger Beer and Tiger Hemp Beer.

Net Savings Link Inc. recently announced that it had acquired a major 25% stake in SBCDF Investment Inc., which is scheduled to launch its STUX product soon. The token; SBC Token Unix X, will be marketed through all major social channels like Medium, Twitter, Telegram, Discord and Reddit. Given that SBC is a force to reckon with not only on Wall Street but also across the globe, NSAV is in for an exciting and fruitful era, which will help the company grow and avail various benefits to its shareholders.

Net Savings Link (NSAV), closed Friday's trading session at $0.0067, up 39.5833%, on 108,873,037 volume. The average volume for the last 3 months is 25,177 and the stock's 52-week low/high is $0.001/$0.0068.

Kun Peng International (KPEA)

We reported earlier on Kun Peng International (KPEA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Kun Peng International Ltd. (OTCQB: KPEA) is a holding firm that is focused on the social e-commerce business, where it offers health care and health related household products.

The firm has its headquarters in Beijing, China and was incorporated in 2020, on September 3rd by Edward Sanders. Prior to its name change, the firm was known as CX Network Group Inc. It operates as part of the internet retail industry, under the consumer cyclical sector. The firm mainly serves consumers in the People’s Republic of China.

The company operates a mobile social e-commerce platform King Eagle Mall, via its King Eagle subsidiary. The platform’s major products include health care products such as dietary supplements, nutritional health foods, beauty cosmeceuticals, and other categories of health foods for supporting the cardiovascular system and bone joint health, such as milk powder and dried fruits. The company also operates KunZhi Jian, an online platform; and Smart Kiosk, which is a physical platform focusing on developing small shop economy. The Smart Kiosk functions as a physical customer service center and community marketing for attracting customers and providing customer services. It also develops online dating applications. The company operates Little Love and Hotchat mobile applications geared towards Chinese singles designed to increase a user's likelihood of finding a romantic connection. This is in addition to operating puzzle casual mobile game applications.

The enterprise, whose average share price recently rose by over 40%, remains focused on generating additional value in the long-term for its shareholders while also bolstering its overall growth.

Kun Peng International (KPEA), closed Friday's trading session at $0.228, up 115.0943%, on 2,300 volume. The average volume for the last 3 months is 12,716 and the stock's 52-week low/high is $0.061/$0.30.

Katapult Holdings (KPLT)

Schaeffer's, FreeRealTime, Trades Of The Day, The Online Investor, QualityStocks, MarketBeat, Daily Trade Alert and BUYINS.NET reported earlier on Katapult Holdings (KPLT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Katapult Holdings Inc. (NASDAQ: KPLT) is an e-commerce financial technology firm that is engaged in the provision of e-commerce point-of-sale lease-purchase options for non-prime customers and retailers.

The firm has its headquarters in Plano, Texas. Prior to its name change in February 2020, the firm was known as Cognical Holdings Inc., before which it was known as FinServ Acquisition Corp. It serves retailers and consumers across the United States.

The company manages a lease-purchase platform dubbed Katapult which offers alternative solutions for consumers and retailers. This end-to-end technology platform enables seamless integration with merchants and allows the company’s retail partners to expand their transactions and customer base. In addition to increasing sales and growing the revenue of its retail partners, its consumer-centric focus ensures tailored payment plans, transparent terms and quick application and approval processes. The company provides instant approvals of up to $3,500.

The enterprise provides its consumers challenged with accessing conventional financial products who seek to acquire everyday durable goods, with a transaction processing system having options for ownership and no long-term obligation. It offers its services to acquire the in-store or online purchases of musical instruments, furniture, appliances and electronics, among others.

The company recently reported its latest financial results which show increases in total revenue. The company’s CEO noted that the company is confident in its strategy to deliver value to its consumers and business partners and is now focused on expanding financial possibilities for its consumers, which will be good for the company’s growth.

Katapult Holdings (KPLT), closed Friday's trading session at $12.76, up 35.7447%, on 46,413 volume. The average volume for the last 3 months is 139,296 and the stock's 52-week low/high is $8.26/$24.76.

Medicenna Therapeutics Corp. (MDNAF)

QualityStocks and TradersPro reported earlier on Medicenna Therapeutics Corp. (MDNAF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company based in Toronto, Ontario. It focuses on oncology and the development and commercialization of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines™ (ECs) for the treatment of a wide array of cancers. Medicenna Therapeutics lists on the OTC Markets Group’s OTCQB.

Medicenna Therapeutics is developing an innovative set of tunable Superkines™, which can be fused with pro-apoptotic proteins to precisely deliver potent cell-killing agents to cancer cells, the immunosuppressive tumor micro-environment and cancer stem cells without harming healthy cells.

Supported by a US$14.1M non-dilutive grant from CPRIT (Cancer Prevention and Research Institute of Texas), Medicenna Therapeutics’ lead IL4-EC, MDNA55, has completed enrolling patients in a Phase 2b clinical trial for rGBM, the most common and uniformly fatal form of brain cancer, at top-ranked brain cancer centers in the United States. MDNA55 has been studied in five clinical trials involving 132 patients. This includes 112 adults with rGBM.

MDNA55 has demonstrated compelling efficacy. Moreover, it has obtained Fast-Track and Orphan Drug status from the FDA (Food and Drug Administration) and FDA/EMA (European Medicines Agency) respectively. MDNA55 targets Temodar-resistant tumors. Delivery by CED infusion of MDNA55 bypasses the BBB (Blood Brain Barrier). Precision delivery achieves high doses without systemic exposure.

Medicenna also develops MDNA57 for solid tumors and on-malignant cells of the tumor micro-environment; and MDNA109, an IL-2 agonist to treat cancer immunotherapies. The Company also develops MDNA209, an IL-2 antagonist for autoimmune diseases; and MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis. Furthermore, Medicenna develops MDNA132, an IL-13 agonist to treat solid tumors, and IL 13Ralpha2 chimeric antigen receptor T cell.

Medicenna Therapeutics Corp. (MDNAF), closed Friday's trading session at $1.82, up 30%, on 577,695 volume. The average volume for the last 3 months is 11.081M and the stock's 52-week low/high is $0.151251/$1.92.

Cyngn (CYN)

QualityStocks, The Street, MarketClub Analysis, StreetInsider, Money Morning, The Trading Report, The Tycoon Report, The Stock Enthusiast, Street Insider, Zacks, 360 Wall Street, Money and Markets, TradingAuthority Daily, MarketBeat, InvestorPlace, Market Report, AllPennyStocks and SmarTrend Newsletters reported earlier on Cyngn (CYN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cyngn (NASDAQ: CYN), a developer of AI-powered autonomous driving software solutions for industrial applications, recently announced the closing of its public offering. The offering was made on a firm commitment basis with gross proceeds of $5.0 million, before deductions. According to the announcement, the offering consisted of 50,000,000 shares of common stock and pre-funded warrants, with each sold at a purchase price of $0.10 per share (or $0.09999 per pre-funded warrant after reducing $0.00001 attributable to the exercise price of the pre-funded warrants). In addition, Cyngn granted Aegis Capital Corp., the sole bookrunner for the offering, a 45-day option to purchase up to 15% of the number of shares and pre-funded warrants sold in the offering to cover any over-allotments. The company expects to use the net proceeds from the offering for general corporate purposes, including working capital.

To view the full press release, visit

About Cyngn

Cyngn develops and deploys scalable, differentiated autonomous vehicle technology for industrial organizations. Cyngn’s self-driving solutions allow existing workforces to increase productivity and efficiency. The company addresses significant challenges facing industrial organizations today, such as labor shortages, costly safety incidents, and increased consumer demand for eCommerce. Cyngn’s DriveMod Kit can be installed on new industrial vehicles at end of line or via retrofit, empowering customers to seamlessly adopt self-driving technology into their operations without high upfront costs or the need to completely replace existing vehicle investments. Cyngn’s flagship product, its Enterprise Autonomy Suite, includes DriveMod (autonomous vehicle system), Cyngn Insight (customer-facing suite of AV fleet management, teleoperation, and analytics tools), and Cyngn Evolve (internal toolkit that enables Cyngn to leverage data from the field for artificial intelligence, simulation and modeling). For more information, visit the company’s website at

Cyngn (CYN), closed Friday's trading session at $0.1098, up 1.4787%, on 13,995,123 volume. The average volume for the last 3 months is 236,617 and the stock's 52-week low/high is $0.10/$1.248273.

Serve Robotics (SERV)

MarketBeat, InvestorPlace, MarketClub Analysis, Market Report, StreetInsider, Zacks, SmallCapVoice, The Street,, BUYINS.NET, Barchart, StreetAuthority Daily, Streetwise Reports, TradersPro, Trades Of The Day, WealthMakers and Schaeffer's reported earlier on Serve Robotics (SERV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Serve Robotics (NASDAQ: SERV), a leading autonomous sidewalk delivery company, recently announced the closing of its underwritten public offering. The offering comprised 10,000,000 shares of common stock at $4.00 per unit, resulting in aggregate gross proceeds of $40 million, before deductions. In addition, Serve granted Aegis Capital Corp., the sole book-running manager, a 45-day option to purchase up to 1,500,000 additional shares of common stock to cover over-allotments. If Aegis exercises the option in full, the total gross proceeds of the offering would be approximately $46 million before deductions. Serve plans to use the net proceeds from the offering to fund research and development of the next generations of Serve’s robots, manufacturing activities, geographic expansion, and for working capital and other general corporate purposes. According to the announcement, Serve’s shares began trading on the Nasdaq Capital Market under the ticker symbol SERV and will no longer trade on the OTCQB(R) Venture Market.

To view the full press release, visit

About Serve Robotics Inc.

Backed by Uber and NVIDIA, Serve Robotics develops advanced, AI-powered, low-emissions sidewalk delivery robots that endeavor to make delivery sustainable and economical. Spun off from Uber in 2021 as an independent company, Serve has completed tens of thousands of deliveries for enterprise partners such as Uber Eats and 7-Eleven. The company has scalable multi-year contracts, including a signed agreement to deploy up to 2,000 delivery robots on the Uber Eats platform across multiple U.S. markets. For more information, please visit

Serve Robotics (SERV), closed Friday's trading session at $2.99, off by 1.6447%, on 198,953 volume. The average volume for the last 3 months is 928,061 and the stock's 52-week low/high is $2.33/$37.00.

Cresco Labs Inc. (CRLBF)

InvestorPlace, QualityStocks, Kiplinger Today, Daily Trade Alert, MarketBeat, Cabot Wealth, Top Pros' Top Picks, The Street, The Wealth Report, The Online Investor, Wealth Insider Alert, Trading For Keeps, Trades Of The Day, Early Bird, Prism MarketView, StreetInsider, wyatt research newsletter, TradersPro and StocksEarning reported earlier on Cresco Labs Inc. (CRLBF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Maine is becoming the new hub for the illegal cannabis trade, with numerous unlicensed cultivation houses scattered across the state, according to a recent investigation conducted by CBS News. This trend mirrors a broader phenomenon unfolding countrywide, with illegal cannabis farms sprouting up in various states, such as Colorado, Oklahoma and California, as highlighted by the DEA’s former head of operations, Raymond Donovan.

Donovan attributes Maine’s strategic suitability for marijuana cultivation to its discreet geographical location and proximity to prominent distribution hubs such as New York and Boston.

A notable instance occurred in December when law enforcement authorities, after a comprehensive six-week probe, conducted a raid in Machias, uncovering a sizable facility housing more than 100 pounds of packaged cannabis and 2,600 plants. Chief of police Keith Mercier described it as one of the largest indoor cannabis cultivation operations he had encountered in his extensive career.

The operation involved a collaborative effort, with Machias police receiving assistance from various agencies including Homeland Security, the U.S. Federal Bureau of Investigation (FBI) and the U.S. Drug Enforcement Administration (DEA), among others. Since June 2023, Maine officials have executed search warrants at 34 properties associated with illegal cannabis activities, with ongoing investigations.

Surprisingly, investigations into the spread of illegal cultivation operations in Maine’s remote areas have pointed to involvement from Chinese organized crime networks. According to Donovan, these networks, which operate internationally, are linked to some of the largest black market cannabis trafficking operations. The issue prompted 50 U.S. legislators to address Merrick Garland, the U.S. attorney general, seeking clarification on China’s involvement in illegal cannabis activities across the country.

Maine Wire editor Steve Robinson has been monitoring the electricity usage of suspected illicit marijuana growers, a key indicator of illicit activity. He observed that such operations consume exorbitant amounts of electricity, necessitating significant upgrades to electrical infrastructure, which are often challenging to obtain.

Mercier acknowledged Robinson’s contributions, mentioning the utilization of his insights as a training tool prior to executing search warrants. The excessive electricity consumption, coupled with other red flags such as shuttered windows, strong odors and suspicious vehicular traffic, led law enforcement to the Machias operation, resulting in the arrest of three individuals on charges of unlawful cultivation.

Donovan highlighted a concerning aspect of the workforce involved in cannabis grow operations, revealing that some Chinese nationals are labor trafficking victims. Exploited under the guise of legitimate employment, these individuals are coerced into overseeing the cultivation process under duress, working under deplorable conditions for minimal compensation.

Further, he noted that the criminal groups are also often involved in more sinister drug trades, including the distribution of fentanyl. The authorities traced the connection between Chinese organized crime and illegal cannabis growers through the fentanyl distribution chain, observing that profits from fentanyl sales often circulate back to Chinese money brokers in Queens and Brooklyn, who are also involved in cannabis trafficking.

Despite marijuana’s legalization in several states, including Maine, its federal illegality persists. The thriving illicit market stems from the disparity between supply and demand, with regulations unable to meet consumer needs. Donovan expressed concern that lenient prosecution could embolden organized crime syndicates to target sparsely populated states such as Maine, exploiting lax oversight to expand their illicit operations.

Licensed companies such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) also have to contend with the marijuana black market in the different markets in which they have operations. Decisively addressing this challenge will go a long way in allowing the legitimate companies in this industry to thrive.

Cresco Labs Inc. (CRLBF), closed Friday's trading session at $2.05, up 5.1282%, on 318,537 volume. The average volume for the last 3 months is 2.814M and the stock's 52-week low/high is $1.00/$2.77.

Hive Blockchain Technologies Ltd. (HIVE)

QualityStocks, InvestorPlace, MarketClub Analysis, MarketBeat, Zacks, CryptoCurrencyWire, StreetInsider, Early Bird,, StockMarketWatch, Stock Market Watch, Greenbackers, Hit and Run Candle Sticks, Barchart, smartOTC, StockOodles, StreetAuthority Daily, The Night Owl, The Online Investor, TopStockAnalysts, Wall Street Resources, WealthMakers and Schaeffer's reported earlier on Hive Blockchain Technologies Ltd. (HIVE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

In a recent statement, Anatoly Aksakov, the Russian State Duma Committee on Financial Market’s chair, noted there’s a push within the BRICS bloc to transition from the U.S. dollar to cryptocurrency for trade purposes. Aksakov emphasized the alliance’s efforts to leverage digital assets instead of traditional fiat currency for international commerce.

The BRICS economic alliance, initially comprised of Russia, Brazil, India, South Africa and China, has long been committed to reducing reliance on the U.S. dollar, advocating for the use of local currencies. Consequently, the creation of digital currency transaction solutions has become a focal point, notably with the introduction of the BRICS Pay system aiming to steer away from dollar dependence.

Over the past year, the trade alliance has actively pursued a multipolar world agenda, evident in its expansion to include five new members at the 2023 annual summit. Emphasizing the importance of local currencies in bilateral trade further underlines this effort. The new member nations include Egypt, Iran, the United Arab Emirates (UAE) and Ethiopia.

The alliance is now prepared to take a significant stride by exploring crypto as an alternative to the U.S. dollar in international trade. Russia highlighted the bloc’s potential as a key conduit for lowering the use of fiat money in international trade. Of particular interest is the bloc’s commitment to creating its Central Bank Digital Currencies (CBDCs) to replace fiat currencies, a stark contrast to the U.S.’s reluctance to engage in such endeavors.

These initiatives present a compelling opportunity for the economic alliance to carry out its dedollarization efforts. Sergey Ryabkov, Russia’s deputy foreign minister, recently discussed plans to establish new financial platforms supporting digital assets over traditional fiat currencies, such as stablecoins.

Ryabkov proposed the creation of the BRICS Bridge, a platform that would integrate the financial systems of member nations and bolster the global monetary landscape by incorporating digital currencies. The initiative offers a clear pathway for the BRICS countries to reduce their dependence on the U.S. dollar. Additionally, Financial Stability Board (FSB) chair, Klaas Knot, noted the significance of tokenization, AI and cryptocurrency assets, indicating a growing interest in digital solutions in international finance.

While transitioning away from the U.S. dollar may raise concerns, especially in unilateral trade agreements with BRICS members, the bloc remains steadfast in its strategy to diversify its currency reserves and foster greater financial autonomy.

As the BRICS actualize their dream to use cryptos for international trade, there is likely to be a positive spillover effect on crypto companies such as Hive Blockchain Technologies Ltd. (NASDAQ: HIVE) (TSX.V: HIVE) since demand will surge and investments will likely pour into the industry.

Hive Blockchain Technologies Ltd. (HIVE), closed Friday's trading session at $3.05, off by 0.651466%, on 1,143,369 volume. The average volume for the last 3 months is 14.931M and the stock's 52-week low/high is $2.535/$6.84.

Newmont Corporation (NEM)

MarketClub Analysis, InvestorPlace, The Street, Schaeffer's, Kiplinger Today, MarketBeat, StocksEarning, Investopedia, The Online Investor, Market Report, Barchart, StreetAuthority Daily, Top Pros' Top Picks, Daily Trade Alert, TopStockAnalysts, QualityStocks, StreetInsider, Louis Navellier, Streetwise Reports, Daily Wealth, SmarTrend Newsletters, Zacks, Money Morning, TradingMarkets, Uncommon Wisdom,, PROFIT CONFIDENTIAL, Trades Of The Day, The Growth Stock Wire, Wealth Daily, TheStockAdvisor, The Wealth Report,, ProfitableTrading, StockEarnings, Wall Street Grand, Trading Tips, Cabot Wealth, Investing Signal, TheStockAdvisors, Dividend Opportunities, The Best Newsletters, Market Intelligence Center Alert, DividendStocks, All about trends, National Inflation Association, InvestorIntel, Trading Markets, AllPennyStocks, InvestmentHouse, Energy and Capital, Market FN, Wyatt Investment Research, MiningNewsWire, Money and Markets, Money Wealth Matters, Stockhouse, Darwin Investing Network, Daily Markets, Street Insider, Wall Street Daily, InvestorsObserver Team, TradingAuthority Daily, Investment House, OTC Stock Pick, Early Bird, Buttonwood Research, Investors Alley, Dynamic Wealth Report, Wall Street Greek, Eagle Financial Publications, StreetAlerts, The Tycoon Report, Investiv, Trading Concepts, Investor News, Market Authority, Trader Jack, Daily Profit, Investing Futures, TipRanks, Short Term Wealth, The Stock Enthusiast, StockTwits, Wealth Insider Alert, 24/7 Trader, Investment U,, FNNO Newsletters, MarketWatch, Investing Daily, Insider Wealth Alert, Candle Stick Forum, ChartAdvisor,, INO Market Report, Global Equity Report, Global Equity Alert, equities Canada, CNBC Breaking News, Total Wealth, Normandy Investment Research, SmallCap Network, Super Stock Picker, The Motley Fool, The Street Report, Seeking Alpha, The Weekly Options Trader, Rick Saddler, Trade of the Week, UndiscoveredEquities, Vantage Wire, VectorVest, Wall Street Window, Weekly Wizards, The Wall Street Transcript, OTCPicks, Investor Update, Investors Insights, Jim Cramer, Leeb's Market Forecast, MarketClub, Small Cap Firm, One Hot Stock, Investor Guide, Penny Detectives, Penny Stock Buzz, PennyStockProphet, Power Profit Trades, Profitable Trader Authority, Profits Run and Navellier Growth reported earlier on Newmont Corporation (NEM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A confluence of geopolitical factors has caused gold prices to surge in recent months and made the precious metal an attractive prospect for many investors. With many countries experiencing rising living costs and high interest rates amid an increase in armed conflicts, investors are looking at gold as a means of diversifying their portfolios and protecting them from volatility.

Many experts are advising investors to buy now before gold prices get out of control. The precious metal has already experienced a major surge in price that has left original holders with significant gains and will likely see continued upward pressure if current geopolitical factors remain as they are.

As such, investing in gold now or in the near term would allow investors to benefit from rising gold prices before the precious metal is out of their price range. Experts predict gold prices will continue to rise in the near term if high inflation rates coupled with the global political landscape don’t undergo any major changes.

Allegiance Gold cofounder Alex Ebkarian says that it is likely gold prices will remain elevated for an “extended period of time.” He noted that it is possible for the precious metal to trade at even higher prices depending on how global “geopolitical tensions and economic issues” play out this year and into next year.

These geopolitical factors include the ongoing Russia-Ukraine war, which has had a major effect on global energy prices, as well as the Gaza conflict, which could potentially spill over into the rest of the Middle East and cause oil prices to surge. In addition, shipping attacks in the Red Sea have threatened to cripple critical international shipping lanes.

Gold prices have jumped significantly in 2024 alone, increasing from around $2,000 an ounce at the start of the year to almost $2,400 per ounce as of April 22.

Investing in gold exchange-traded funds (ETFs) and stocks could also allow investors to profit from increasing gold prices, experts say. According to Ebkarian, gold stocks and ETFs are a smart investment option for investors interested in day trading or short- to medium-term, gold-related investments. Still, he urges investors to do their research before investing in precious metal ETFs as these investment options can expose them to counterparty risk, primarily because custodians manage ETFs and are responsible for each fund’s management and operations.

Investors can also add gold to their portfolios by purchasing physical gold, Global Wealth Advisors’ Kevin Curley says. Curley says that physical gold usually has a “small markup to the spot rate” and can be easily stored in a safety deposit box at the bank or a safe at home. Government data also shows that investing in physical gold can provide investors with a hedge against rising inflation.

AMPEX director of marketing Brett Elliott explains that physical gold functions better as an inflation hedge; it typically has lower costs compared to other types of gold investments.

As gold continues its current upward price movement, investors keen on adding gold stocks to their portfolios are likely to keep an eye on established miners such as Newmont Corporation (NYSE: NEM) (TSX: NGT) to see whether they could be good additions to their holdings.

Newmont Corporation (NEM), closed Friday's trading session at $42.73, off by 1.5665%, on 14,689,213 volume. The average volume for the last 3 months is 45.385M and the stock's 52-week low/high is $29.42/$50.18.

Rivian Automotive Inc. (RIVN)

InvestorPlace, Schaeffer's, QualityStocks, The Street, Kiplinger Today, MarketBeat, MarketClub Analysis, Early Bird, INO Market Report, StockEarnings, Investopedia, The Online Investor, Zacks, GreenCarStocks, Daily Trade Alert, AllPennyStocks, Louis Navellier, StocksEarning, The Night Owl, TipRanks, Trades Of The Day, InvestorIntel, DividendStocks, InvestorsUnderground, Cabot Wealth, BillionDollarClub, 360 Wall Street, FreeRealTime, Top Pros' Top Picks, Top Pros’ Top Picks and bullseyeoptiontrading reported earlier on Rivian Automotive Inc. (RIVN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

With demand for electric vehicles reaching record lows in recent months, an increasing number of automakers are slashing their battery electric vehicle (BEV) prices in an attempt to woo unwilling customers. As a result, nearly 8 in every 10 newly minted electric cars have been sold at some kind of discount amid dwindling consumer demand.

Data from Auto Trader shows that 77% of new electric cars listed on the platform were discounted down from last month’s prices and up to 55% are now cheaper than they were a year prior. Automakers are also offering higher and higher discounts for electric cars, and the average reduction rate currently stands at a record 11%.

Electric vehicle demand has taken a significant plunge since late 2023 due to one major reason; EVs are still too expensive for the average consumer. While the first wave of typically wealthy early adopters was enough to keep the nascent electric vehicle sector going for nearly a decade, most of these folks already own an electric car. Vehicle manufacturers such as Tesla are now struggling to attract the rest of the vehicle consumer market as their purchasing decisions are primarily based on affordability.

Rising interest rates across most countries have also increased the cost of debt and made it more expensive to procure loans. As a result, fewer drivers are willing to acquire an electric car using debt. This has left EV startups and automakers scrambling to attract clientele by slashing their prices. A vicious price discount war started by Tesla in China due to escalating competition also forced other automakers to cut prices as well and caused prices for both new and second-hand electric cars to fall across the board.

Tesla recently announced another round of price cuts in Europe, China and the United States after its sales numbers took a notable hit indicating the electric vehicle giant’s growing inability to attract customers willing to spend a premium on its offerings. The Texas-based automaker cut Model Y prices in China from $37,419 to $34,483, slashed base Model Y prices in the U.S. down to $42,990, and reduced the Model 3 rear wheel drive car’s cost in Germany $2,133 ($1,840) to $43,723.

Auto Trader notes that even though petrol- and diesel-powered cars have also seen an increase in discounts, likely a sign that the entire automobile industry is in turmoil, price cuts in the electric vehicle sector have been more severe. An estimated 31% of electric cars have seen their prices drop by at least one-tenth while only 24% of internal combustion engine (ICE) cars have seen similar discounts.

As things stand, various EV startups such as Rivian Automotive Inc. (NASDAQ: RIVN) across the board now have to work extra hard to stimulate demand for their models in order to remain profitable in the industry.

Rivian Automotive Inc. (RIVN), closed Friday's trading session at $9.04, up 6.1033%, on 28,226,128 volume. The average volume for the last 3 months is 53.848M and the stock's 52-week low/high is $8.26/$28.06.


InvestorPlace, The Street, Kiplinger Today, Zacks, Schaeffer's, MarketClub Analysis, The Online Investor, MarketBeat, Trades Of The Day, Daily Trade Alert, Early Bird, StreetInsider, Investopedia, StocksEarning, Market Intelligence Center Alert, The Wealth Report, Cabot Wealth, Top Pros' Top Picks, Barchart, Wealth Insider Alert, Louis Navellier, Jason Bond, InvestorGuide, TipRanks,, INO Market Report, The Street Report, Money Morning, Daily Wealth, TopStockAnalysts, Trading Tips, CNBC Breaking News, StreetAuthority Daily, StockEarnings, DividendStocks, Market Report, The Night Owl, Trading Markets, Street Insider, Money Wealth Matters, Investor Guide, InvestmentHouse, Trading Concepts, StockMarketWatch, StreetAlerts, TradersPro, MarketTamer, AllPennyStocks, Greenbackers, Money and Markets, The Motley Fool, TheStockAdvisors, Eagle Financial Publications, SmarTrend Newsletters, Market Intelligence Center, MarketWatch, VectorVest, The Best Newsletters, Daily Markets, ProfitableTrading, Investing Lab, Short Term Wealth, Investment House, Power Profit Trades, StrategicTechInvestor, Profit Confidential, TheStockAdvisor, QualityStocks, Investors Alley, Stockhouse, Investing Daily, Wealth Daily, InsiderTrades, Investment U, Stock Gumshoe, Buttonwood Research, TradingMarkets, Jon Markman’s Pivotal Point, Darwin Investing Network, Contrarian Outlook, Earnings360, Market FN, Investing Futures, InvestorIntel, bullseyeoptiontrading, The Daily Market Alert, GorillaTrades, WStreet Market Commentary, BUYINS.NET, Market Trends, Traders For Cash Flow, Trade of the Week, CustomerService, internetnews, internet, SmartMoneyTrading, Shah's Insights & Indictments, TheOptionSpecialist, Total Wealth, InvestorsObserver Team, Wyatt Investment Research, The Stock Dork, FreeRealTime, Prism MarketView, Schaeffer’s, Profits Run, TradeSmith Daily, Investor's Business Daily, TradingPub, AnotherWinningTrade, FeedBlitz, SmallCapVoice, Investors Underground, Investor News, Uncommon Wisdom, Stock Research Newsletter, Jeff Bishop, Investing Breakout, Average Joe Options, CRWEFinance, Insider Wealth Alert, Inside Trading, INO Traders Blog, Hit and Run Candle Sticks, 24/7 Trader, GreatStockPix, Stock Up Featured, Penny Sleuth, Timothy Sykes, Tim Bohen, Dawn Report, OilAndEnergyInvestor, Top Secret Stocks, Daily Profit, MarketClub, Sling-Shot-Stocks, Prime Group, Trading with Larry Benedict, Profitable Trader Authority, The Growth Stock Wire, Rick Saddler, Jim Cramer, SiliconValley, Chaikin Analytics, Dividend Opportunities, Chaikin PowerFeed, DTI Trader, Dynamic Wealth Report, Coattail Investor,, 247 Market News, Energy & Resources Digest, FNNO Newsletters, CRWEWallStreet, 360 Wall Street, 360wallstreet, ChartPoppers and BestOtc reported earlier on NVIDIA Corp. (NVDA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

An artificial intelligence (AI)-powered telemedicine platform launched in Germany is looking to improve the quality of medical care provided to coronary artery disease patients. The condition results in nearly two million heart attacks and 610,000 deaths annually but can be addressed with early treatment coupled with rehabilitation to help patients make positive lifestyle changes.

Launched by Dr. Boris Schmitz, a German sports scientist, biologist and PD, the Timely Project looks to create a patient-centered platform that will use AI and e-health to provide early cardiac risk predictions as well as support post-rehabilitation prevention and intervention in coronary artery disease (CAD) patients.

Although rehabilitation clinics help CAD patients develop positive lifestyle habits such as exercising, eating a healthy diet and reducing their stress levels to prevent re-infarction and allow them to live with the condition for as long as possible, the patients often struggle with sticking with these habits once they go back home. Schmitz, who is also a senior scientist at Königsfeld Clinic’s Center for Clinical Rehabilitation, notes that the “first six months after rehab” are critical because this is the period when changes in behavior slowly turn into habits.

However, Schmitz says, there is basically no postrehab care for CAD patients aside from one follow-up cardiologist visit after half a year.

The scientist wants to use the Timely platform alongside a randomized, controlled clinical study involving 360 adult CAD patients to show how cardiovascular risk can drop by using the Timely platform. He is conducting the project in three study centers with 13 industry partners; the centers are located in the Netherlands, Spain and Germany.

Schmitz says the research team onboarded CAD patients who had gone through myocardial revascularization after the diagnoses at the start of their rehab. The research team interviewed the patients, learned about their needs and wishes, and then tested the platform’s user friendliness.

Study participants receive a blood pressure monitoring device, an activity tracker, and a portable, wireless 3-lead ECG that collect data on stress levels, activity calories, speed of blood flow and blood vessel resistance.

The Timely app will provide CAD patients with all the information they need regarding rehab, weight loss, stress management and diet to help them set personal goals. It will also send personal messages that feature a chatbot, which provide regular positive reinforcement to help patients stay motivated.

The platform and app will use artificial intelligence to process all the data collected during the study and detect potential arrhythmias early using factors such as increased stress levels or changes in sleeping rhythm, Schmitz explains.

All these advancements in AI within different industries are being made possible by the surge entities such as NVIDIA Corp. (NASDAQ: NVDA) have made in availing advanced microchips to make it possible to train large language models and other systems needed to break new ground in key industries.

NVIDIA Corp. (NVDA), closed Friday's trading session at $877.35, up 6.1756%, on 55,101,078 volume. The average volume for the last 3 months is 100.625M and the stock's 52-week low/high is $266.2501/$974.00.

Tesla Inc. (TSLA)

The Street, InvestorPlace, Green Car Stocks, StreetInsider, Schaeffer's, Kiplinger Today, Investopedia, Zacks, MarketClub Analysis, MarketBeat, The Online Investor, Daily Trade Alert, Money Morning, Options Elite, StreetAuthority Daily, Trades Of The Day, Market Intelligence Center Alert, Cabot Wealth, Early Bird, All about trends, Energy and Capital, StocksEarning, Wealth Daily, TopStockAnalysts, CNBC Breaking News, InvestorGuide, Uncommon Wisdom, Barchart, The Motley Fool, Street Insider, MarketWatch, Daily Profit, Louis Navellier, StockEarnings, Profit Confidential,, AllPennyStocks, Money and Markets, Trading Tips, Investors Alley, ProfitableTrading, InvestorIntel, Alternative Energy, Top Pros' Top Picks, SmarTrend Newsletters, INO Market Report, Wyatt Investment Research, Wealth Insider Alert, StrategicTechInvestor, Wall Street Daily, TipRanks, Investor Guide, Investing Daily, The Wealth Report, Money Wealth Matters, Greenbackers, Market Intelligence Center, Investment U, CustomerService, FreeRealTime, smartmoneytrading, MarketTamer, The Street Report, Stock Up Featured, Market Report, Trading Concepts, Wall Street Elite, Daily Wealth, Hit and Run Candle Sticks, Eagle Financial Publications, wyatt research newsletter, Investiv, National Inflation Association, The Growth Stock Wire, Jon Markman’s Pivotal Point, SureMoney, Short Term Wealth, StockMarketWatch, Wall Street Profit Search, Investing Futures, GorillaTrades, Market Authority, Insider Wealth Alert, Streetwise Reports, QualityStocks, Darwin Investing Network, Dynamic Wealth Report, Stock Barometer, equities Canada, Total Wealth, Stock Gumshoe, SmallCapVoice, The Night Owl, Inside Investing Daily, The Stock Dork,, DividendStocks, Average Joe Options, Rockwell Trading, TheStockAdvisors, SmallCap Network, Bourbon and Bayonets, Power Profit Trades, Rick Saddler, InvestorsUnderground, The Best Newsletters, Dividend Opportunities, Trade of the Week, Daily Dividends, Investor News, WStreet Market Commentary, Investment House, FeedBlitz, The Trading Report, Outsider Club, TradersPro, Wall St. Warrior, Contrarian Outlook, BUYINS.NET,, Shah's Insights & Indictments, OilAndEnergyInvestor, Direction Alerts, Stock Tips Network, TheOptionSpecialist, InvestorsObserver Team, bullseyeoptiontrading, 360wallstreet, InvestmentHouse, 777 Stocks, Economic News Room, BullDogReporter, Market FN, Market Trends, Jason Bond, Investor Ideas, Trader Prep, SmallCapNetwork, Schaeffer’s, The Wall Street Transcript, The Weekly Options Trader, Stock Analyzer, Prism MarketView, Terry's Tips, Visual Capitalist, Wall Street Window, Options Trader Elite, Penny Sleuth, Wealthpire Inc., 24/7 Trader, Investing Signal, Investing Lab, Super Stock Investor, Investing Breakout, OptionAlarm News, The Daily Market Alert, GreenCarStocks and The SmartMoneyTrading reported earlier on Tesla Inc. (TSLA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tesla Inc. (NASDAQ: TSLA) is calling back its Cybertrucks after issues with faulty pedal pads that could cause accelerator pedals to get stuck were noted. Specifically, it was reported that when drivers pressed their feet down on the accelerators, the pads could come off and become trapped in the interior trim, which increased the risk of a collision by leaving the accelerator stuck.

This issue is said to have emerged on production lines with soap, as reported by the auto manufacturer to the National Highway Transportation Safety Administration.

In the report, Tesla revealed that some changes saw the introduction of soap in component assembly. It is believed that workers used soap as a lubricant to help attach pads onto pedals, which left traces of the slippery lubricant on the pedal.

The issue was first raised on March 31, 2024, by one customer, then verified by Tesla Engineering on April 2, 2024, after engineers reviewed data logs and confirmed the presence of the issue. A second customer raised a similar issue a day later, and after concluding its evaluations on April 12, 2024, the automaker made the decision to voluntarily recall the affected trucks.

This call back involves more than 3,800 Cybertrucks that have been sold to consumers thus far.

Normally, software fixes by Tesla are issued directly, with users only required to download updates, which eliminates the need to go to a mechanic. However, since this is a physical issue, all trucks will need to be repaired by the automaker.

This isn’t the first soap-related manufacturing issue to be reported either. Earlier this year, a supplier of Boeing spoke in support of Dawn dish soap being used as a lubricant in the assembly of door seals in manufacturing jets such as the Boeing 737 Max 9 plane, which lost a door during a flight.

In addition to this soap problem, the Cybertruck has had other complaints surface since its launch, one of them being rust. Some customers have posted images on social media showing rust spots in the vehicles’ exterior, some of which start to show after the vehicle has been driven in the rain.

The Cybertruck has an unusual manufacturing process, with the stainless-steel body panels being welded together to form its structure. In its official statement, Tesla told investors that it was between periods of growth. This comes after the auto manufacturer laid off more than 10% of its global staff and announced poor sales during the previous quarter.

Executives are set to talk to investors next week on a scheduled quarterly earnings call.

Tesla Inc. (TSLA), closed Friday's trading session at $168.29, off by 1.1106%, on 109,815,725 volume. The average volume for the last 3 months is 24,424 and the stock's 52-week low/high is $138.8025/$299.29.

The QualityStocks Company Corner

Turbo Energy S.A. (NASDAQ: TURB)

The QualityStocks Daily Newsletter would like to spotlight Turbo Energy S.A. (NASDAQ: TURB).

The European Union recently signed its inaugural ‘European Solar Charter', aimed at driving the growth of the continent's solar industry

Turbo Energy has emerged as one of the leading companies within the European solar supply chain, with its array of residential and industrial energy storage solutions

The company recently revealed that its range of ‘GoSolar' residential solar energy solutions would be distributed by El Corte Ingles, Europe's largest department store chain

Turbo Energy also announced its FY2023 financial results, revealing FY23 revenues of USD 14.54 million

The European Commission and representatives of the continent's solar energy parts manufacturers came together on April 15th to sign a charter, aimed towards achieving resilient within the European Union's solar value chain and help meet the bloc's renewable energy targets ( A key element of the European Solar Charter signed by 23 of the 27 EUR countries, signaled a commitment from the signatory governments to realize the pending Net-Zero Industry Act ("NZIA"), legislation which will aim to ensure that the EU will have the manufacturing capacity for renewable technologies, including photovoltaics, nears 40 percent of annual deployment needs by 2030. The European Union sourced 23 percent of its energy needs from renewable sources in 2022, largely driven by solar energy; nevertheless, that proportion seems likely to increase dramatically in upcoming years. The EU has set a new target of sourcing 42.5 percent of its energy needs from renewable sources for 2030, an ambition which will require a double of the rate of renewables deployment seen over the past decade alongside an ongoing transformation of the European energy system ( Turbo Energy (NASDAQ: TURB), a designer, developer and manufacturer of photovoltaic energy generation, management, and storage equipment is one of the companies striving to help meet this objective through its range of power storage solutions. The company's GoSolar range, an array of lightweight and portable solar energy solutions, seeks to provide consumers with cost-effective options for reducing electric bills and minimize their carbon footprint ( Designed for easy installation and compatibility with most household outlets, GoSolar will provide households with an accessible route towards renewable energy adoption.

Turbo Energy S.A. (NASDAQ: TURB) designs, develops and distributes equipment for the generation, management and storage of photovoltaic energy in Spain, Europe and internationally.

Turbo Energy’s products include lithium-ion batteries and inverters. Additionally, the company recently launched its flagship product, the Sunbox, an all-in-one device that integrates most of the equipment required for a residential photovoltaic installation. The Sunbox is powered by AI and features a software system that monitors the generation, use and management of photovoltaic energy by analyzing large amounts of data related to energy generation, consumption, market prices and weather forecasts. This AI system optimizes battery usage, reducing electricity bills and providing peak-use reduction and uninterruptible power supply functions.

Turbo Energy currently sells its photovoltaic energy equipment primarily through distributors for residential consumers in Spain, but it possesses the expertise and international perspective to expand its product portfolio into industrial and commercial scale and markets, as well as advancing the internationalization process it has already started. The company plans to expand into the industrial photovoltaic sector with its new Sunbox, launched in 2023, in higher power and capacity variants. Its goal is to become a significant player in this sector and contribute to the growth of renewable energy solutions.

The company was incorporated in 2013 and is based in Valencia, Spain. It operates as a subsidiary of Umbrella Solar Investment S.A.


Lithium-Ion Batteries

Turbo Energy is one of the leading companies that introduced lithium-ion batteries for photovoltaic energy storage in Spain. Primarily for the home energy storage market, the company’s batteries have capacities from 2.24 kWh to 5.1 kWh in 24 and 48 volts. In addition, its 48V / 5.1 kWh units are available in a dual battery system.


The inverter converts the direct current produced by the photovoltaic panels into alternating current that can be used by household appliances. It also regulates battery charging and discharging based on energy needs and optimizes utilization of generated renewable energy. Turbo Energy currently offers multiple models that cover most household installations.

All-in-One Sunbox

This product incorporates inverters, batteries and the rest of the components necessary to operate and protect the photovoltaic installation. This saves installation cost and assembly and configuration time while preventing errors. Notably, the latest Sunbox models also offer an EV charging option.

Software System

In communication with the inverter, the company’s software monitors energy flows between the photovoltaic panels, household consumption, storage and an optional electric vehicle charging station. The software allows users to customize an automatic backup mode based on weather forecasts, or manually select which part of the battery will be reserved for possible power outages. It also allows the battery to be used in a peak shaving mode, which leverages AI to trigger battery power when grid energy is most expensive, effectively reducing the amount of high-cost power drawn from the grid.

Market Opportunity

According to a report by Fortune Business Insights, a global research and reporting firm, the solar energy storage battery market was estimated to be worth $3.33 billion in 2022 and is projected to reach a value of more than $20 billion by 2030, marking a CAGR of 24.2% over the forecast period.

These batteries are crucial components of renewable energy systems, allowing for the storage of excess electricity generated by solar panels, so it can be used during times of no or low sunlight. By storing energy and supplying it when needed, these batteries reduce reliance on the power grid and maximize self-consumption while helping users avoid peak electricity rates. They also contribute to the transition toward a cleaner and more sustainable energy future by enabling residential consumers and businesses to use solar power even when the sun is not shining.

Management Team

Enrique Selva Bellvís is the CEO and founder of the Umbrella Group. In addition, he serves as vice-president of the Valencian Association of Energy Sector Companies industry group. Before his career in the solar energy sector, he was the founder and CEO of Innova Ingenieros Consultores. He holds a degree in industrial engineering with a specialization in energy from the Polytechnic University of Valencia and completed the Management Development Programme at the IESE Business School.

Mariano Soria is the Chief Innovation Officer for the Umbrella Group and serves as General Manager of Turbo Energy. He was CEO of Punt Moble XXI S.L. and continues to serve on that company’s board. Before that, he was the General Manager of REJMAR S.A., a land development company. He received his degree in industrial engineering and industrial organization from the Polytechnic University of Valencia, and his MBA from the European University of Madrid.

Alejandro Moragues is CFO of Turbo Energy. Previously, he held the position of Senior Corporate Auditor for U.S. company Euronet Worldwide Inc. and was an external auditor for PricewaterhouseCoopers. He holds a bachelor’s degree in business administration and management from the Polytechnic University of Valencia.

Manuel Cercos is Chief Commercial Officer at Turbo Energy. Previously, he held positions at Técnicas Aplicadas en Baterías S.L., where he served as Sales Director and Sales Manager. Before that, he worked as a Sales Technician at DAISA.

Turbo Energy S.A. (NASDAQ: TURB), closed Sunday's trading session at $1.1501, off by 4.1583%, on 20,353 volume. The average volume for the last 3 months is 73 and the stock's 52-week low/high is $0.855/$7.90.

Recent News

Torr Metals Inc. (TSX.V: TMET)

The QualityStocks Daily Newsletter would like to spotlightFathom Torr Metals Inc. (TSX.V: TMET) .

Copper is expected to play an increasingly important role in powering the world's transition towards net zero technologies

The average electric vehicle can contain up to 183lbs of copper, a massive 277% increase relative to internal combustion engine cars

The surge in copper demand is expected to drive a necessary increase in supply, requiring an additional 9.7 million metric tons (Mt) production per annum by 2031. With a deficit of 114,000 tonnes projected for 2023, the copper supply is anticipated to remain in deficit by the beginning of the next decade with a forecasted shortfall of 6.5 Mt

Torr Metals is looking to fill that supply imbalance through two ongoing highway-accessible copper-gold porphyry projects within two of Canada's most prolific copper mining districts

Recent findings in the company's Kolos Copper-Gold Project have been extremely promising and suggestive of a significant new copper porphyry discovery, within 30 kilometers of Canada's largest open pit copper mine at Highland Valley

Global warming has become an undeniable force around the globe, with news of widespread droughts, record temperatures, forest fires, and ravaged agricultural harvests increasing in frequency. In response, global leaders came together during 2021's COP26 event in Glasgow to propose a global Net Zero initiative, aimed towards achieving a balance between global greenhouse gas ("GHG") emissions and those being removed from the atmosphere. Whilst a number of countries have since published their own legislation, detailing the measures and timeframes through which they expect to achieve a net zero status, there is a common consensus amongst all – the change will not be easy. Forecasts by the International Energy Agency now suggest that to reach global net zero emissions by 2050, annual clean energy investment around the globe will need to more than triple to approximately $4 trillion per annum by 2030 ( Vancouver-based Torr Metals (TSX.V: TMET), a mineral exploration company focused on the identification, acquisition and advancement of mineral properties has sought to address this burgeoning supply-demand imbalance, through its holdings of over 1,000 square kilometers of gold and copper projects, spread across an array of premier low-cost mining jurisdictions, some of which have resulted in promising findings to date – the Kolos Project chief amongst these.

Torr Metals (TSX.V: TMET), a Vancouver-based mineral exploration company, has been featured in an interview with Proactive. TMET CEO Malcolm Dorsey joined Steve Darling from Proactive to announce preliminary results that have identified near-surface high-priority geophysical resistivity anomalies extending up to 1.5 kilometers in depth. The announcement noted that these anomalies are coincident with highly anomalous copper, gold, and molybdenum mineralization at the surface. These findings represent a significant step forward in the exploration efforts of Torr metals, potentially unlocking valuable mineral resources in the Kolos Copper-Gold Project. "We are waiting on our drill permits, but over the next couple of months, we also have other plans. One of the other things we announced was that the geophysics indicates significant extension potential within both the Clapperton and Kirby zones. With Kirby, it looks like the geophysics extends another 1,900 meters to the south. So, this is something we will go back [to]; we will do some additional soil [sampling] to test these extensions whilst we look into doing some IP grids over the main target areas. This will really help with future drill targeting that we have planned potentially for 2024," said Dorsey of the company's plans. To view the full press release, visit

Torr Metals Inc. (TSX.V: TMET) operates as a mineral exploration company focusing on the identification, acquisition, and advancement of mineral properties. With full 100% ownership of over 1,000 square kilometers of gold and copper projects strategically positioned in premier low-cost mining jurisdictions, Torr is poised for substantial returns across various promising regions.

The company’s extensive portfolio encompasses multiple district-scale projects, including the Filion Gold Project in northern Ontario, the Kolos Copper-Gold Project in south-central British Columbia, and the Latham Copper-Gold Project in northern British Columbia. These projects are all located in prolific mining regions with paved highway access, robust support infrastructure, and favorable geological conditions offering significant potential for new discoveries.

Headquartered in Vancouver, British Columbia, Torr Metals is ideally situated to leverage its expertise and resources for continued exploration and growth.


Kolos Copper-Gold Project

Situated within British Columbia’s prime copper-producing belt, the 140-square-kilometer Kolos Copper-Gold Project exhibits Nicola Belt geology similar to notable porphyry mines, including Copper Mountain and Highland Valley, respectively situated 106 kilometers to the south and 30 kilometers to the northwest.

With field operations based in the nearby city of Merritt and year-round access provided via Highway 5, the Kolos Project showcases substantial discovery upside potential with five defined large-scale copper-gold-molybdenum anomalies untested by drilling.

Torr Metals’ primary focus lies in unlocking the potential for major new discoveries at the Kolos Copper-Gold Project, with recent surface geochemical results marking a significant milestone positioning the company as a new key player in the region.

Filion Gold Project

The 261-square-kilometer Filion Project is situated within a largely unexplored greenstone belt where gold was initially discovered in the 1930s. With a comparable geological setting to regional orogenic gold deposits and multiple newly identified and undrilled gold trends in surficial geochemistry, the Filion Project holds significant district-scale exploration promise.

The Filion Project benefits from unparalleled infrastructure access, with direct drive-on access from the Trans-Canada Highway, as well as a regional railway and power grid four kilometers to the south. Additionally, the nearby town of Kapuskasing, with a population of 8,300, provides essential support services.

This strategic positioning ensures the Filion Project’s viability for cost-effective, year-round operations in an area poised for untapped discovery potential.

Latham Copper-Gold Project

Situated in British Columbia’s renowned Golden Triangle, the Latham Project spans a vast 689-square-kilometer district, offering immense potential for multiple major discoveries. Accessible year-round via Highway 37, just 20 kilometers south of the town of Dease Lake, the site is strategically located amidst established mining infrastructure, including the active Red Chris mine to the southeast and upcoming major porphyry projects at Schaft Creek and Galore Creek along-trend to the southwest.

Highlighted by the Gnat Pass copper-gold porphyry deposit dating back to the 1960s, the Latham Project presents a compelling opportunity for significant expansion and potential discovery. A non-compliant indicated resource at the Gnat Pass deposit includes 33 million tonnes at 0.39% copper, open beyond 200 meters vertical depth, alongside six drill-ready kilometer-scale copper-gold exploration targets.

Moreover, the Latham Project’s appeal corresponds to the region being an attractive destination for major asset acquisitions and takeovers. Recent transactions within a 40-kilometer radius include Newmont’s 2021 acquisition of the Saddle North copper-gold porphyry deposit for $311 million and Newcrest’s investment in the Red Chris copper-gold porphyry deposit in 2019 for $804 million, underscoring industry acknowledgment of the region’s potential.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 that the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion.

The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth. This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

Likewise, a report from Acumen Research and Consulting, a global provider of market intelligence and consulting services, valued the global copper market at $304.1 billion in 2022 and forecast that it will reach a market size of $496.8 billion by 2032, growing at a CAGR of 5.1% over the forecast period.

The report identifies a growing demand for copper in the electronics industry, as well as an expanding copper supply due to increasing production from existing mines and the rising number of mine development projects in developing nations, as driving factors in the rising value of the copper market.

Management Team

Malcolm Dorsey, P.Geo., is President, CEO and Director of Torr Metals. He brings over a decade of expertise as a seasoned exploration geologist and project developer, having been pivotal in driving the success of numerous diverse projects across North, Central, and South America. His comprehensive background spans early-stage exploration through to resource development and project acquisitions. His academic credentials include an M.Sc. in Geology and Geophysics from the University of Calgary, where his research characterized the district-scale structural influences affecting copper and gold mineralizing events in western British Columbia. Prior to his current role, he served as Senior Geologist for Benchmark Metals, where his contributions were instrumental in advancing the company’s gold equivalent resource from approximately 80,000 ounces to a maiden resource estimate of 2.92 million ounces.

John Williamson, P. Geol., is Chairman and Director of Torr Metals. He is a mining executive and investor with more than 30 years of experience as a founder, promoter and leader in the formation, financing and operation of private and public companies with exploration and mining interests worldwide. On more than one occasion his team’s efforts have been recognized for excellence by being named to the TSX Venture 50. He holds a B.Sc. in Geology and is a registered Professional Geologist (P.Geol.) with the Association of Professional Engineers and Geoscientists (APEGA) and the Geological Association of Canada.

Torr Metals Inc. (TSX.V: TMET), closed Sunday's trading session at $28.745, off by 0.294832%, on 36 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $7.90/$.

Recent News

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF)

The QualityStocks Daily Newsletter would like to spotlight Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF).

Despite the recent surge in corporate sustainability commitments across several industries, top environment, sustainability and governance experts are becoming increasingly disillusioned with the lack of proper commitment by companies. The result is a notable increase in senior ESG professionals searching for new employment opportunities after realizing that their bosses were not as serious about committing to sustainability practices as they initially claimed. TWS Search Partners founder and sustainability market headhunter Tom Strelczak says he has seen an increase in the number of inquiries from candidates dissatisfied with their previous positions in Q1 2024. According to Strelczak, some ESG specialists are beginning to feel like their sustainability positions were just "glorified risk-management functions" rather than impactful positions. However, Strelczak says American-centric asset managers stopped "shouting" about ESG when things got tough and senior ESG employees realized their impact would be quite limited. Consequently, the headhunter says, many ESG experts are leaving their glitzy jobs at asset-management companies and trying to move to other firms companies are more committed to ESG where they "can actually be heard." These reports of disillusioned ESG professionals cast a shadow on the successes that many entities such as Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) are registering in the integration of ESG practices in all their operations and reaping the benefits of those efforts.

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) is a strategic minerals company focused on locating and developing economic properties in the strategic metals and advanced materials space. The company aims to improve domestic specialty mineral infrastructure efficiencies to meet surging national demand from North American manufacturers, effectively positioning itself as one of the only North American suppliers of high purity natural graphite for hi-tech applications.

Reflex Advanced Materials is based in Vancouver, British Columbia. Its project portfolio includes the Ruby Graphite Deposit in Montana and the ZigZag Lithium Property in Ontario.


Ruby Graphite Project

Located in a mining-friendly jurisdiction in southwest Montana, the Ruby Graphite Deposit is a low cost, rapid re-entry opportunity that produced roughly 2,400 tons of graphite from 1902 to 1948. Reflex Advanced Materials holds mining rights for 755 hectares at the Ruby Graphite Project, with 96 federal lode mining claims. Recent samples assay at 95.8% to 98.4% total carbon.

The site is notable as the only combined U.S. graphite flake and vein graphite source. Vein graphite is ideal for energy storage applications, because it requires fewer steps to achieve purity than synthetic alternatives and is therefore far less environmentally damaging. This is expected to play a key role in the project’s development as demand for electric vehicles continues to surge.

In March 2023, the company announced its submittal of permit applications to the Bureau of Land Management in respect of its exploration of the Ruby Graphite Project. Its initial drill program, expected to take place in the summer of 2023, includes plans for 3,500 total meters of drilling, cored to an average depth of 130 meters. The targets for this drill program have been identified using historical data from original mine operations and data gathered for the initial 43-101 technical report on the project, dated January 31, 2023.

ZigZag Lithium Property

Located in the Thunder Bay Mining Division of Ontario, the ZigZag Lithium Property consists of eight mining claims spanning roughly 2,710 hectares. Mineralization at the property, most notably lithium, is based in pegmatite dikes and concentrated in spodumene crystals, which are consistent throughout the entire unit.

Spodumene is readily observable in outcrops and in drill cores, with crystal sizes ranging from 3-15cm, on average.

Reflex Advanced Materials and American Energy Technologies Company Metallurgical Partnership

Reflex Advanced Materials has entered into a material processing agreement with American Energy Technologies Co., which is based in Arlington Heights, Illinois, to conduct metallurgical testwork with the goal of creating a technical support data package for Reflex’s target customer base, U.S. Federal agencies and qualification programs with hi-tech customers in the battery and battery storage business.

The resulting coated, spherionized, purified graphite (CSPG) material that is expected to be created from the aforementioned tests will be used to provide potential customers of CSPG with samples so that they can begin the material qualification process.

Market Opportunity

Graphite is an ideal battery anode and has dominated the market since the proliferation of lithium-ion batteries. Despite this demand, there is currently no significant production of lithium-ion battery anode material in North America.

Instead, most graphite sold in North America today is sourced from Chinese producers. U.S. President Joe Biden highlighted this sourcing disparity in a 2022 address:

“The United Stated depends on unreliable foreign sources for many of the strategic and critical materials necessary for the clean energy transition – such as lithium, nickel, cobalt, graphite and manganese for large-capacity batteries,” he said. “Demand for such materials is projected to increase exponentially as the world transitions to a clean energy economy.”

The U.S. Department of Energy is in the process of awarding $2.8 billion to expand domestic manufacturing of batteries for electric vehicles and combat this foreign dependency. Reflex Advanced Materials has identified its Ruby Graphite Project as a prime candidate for U.S.-sponsored initiatives due to the rarity and scarcity of natural graphite deposits in the country.

Processing graphite domestically in the U.S. is expected to provide Reflex Advanced Materials a competitive advantage as manufacturers begin to seek out American supply in the face of increased diplomatic tension. This is critical, as a rise in anode demand is expected to fuel a shortage of 8 million tonnes of graphite by 2040. World Bank Group projects 494% growth in total graphite demand by 2050.

Leadership Team

Paul Gorman is the CEO and a Director of Reflex Advanced Materials. He brings to the company over 25 years of experience in junior mining finance, public listings, viability assessment and operational rationalization. For 18 years, Mr. Gorman served as president and managing partner of Riverbank Capital, where he played an instrumental role in raising more than $85 million for small-cap companies. In 2008, he funded Industrial Minerals Inc. (later Northern Graphite) and served in an advisory role for four other graphite companies, contributing significantly to the revitalization of the junior graphite space in North America. Mr. Gorman founded Mega Graphite Inc. in 2009 and has served as chief executive for three other companies.

Tasheel Jeerh, CPA, is the company’s CFO. He is a finance and accounting professional with over a decade of experience spanning both public and private sectors. Prior to joining Reflex Advanced Materials, Mr. Jeerh played a pivotal role in the growth of a private upstream oil and gas firm, dealing with over $2 billion in M&A activity and $1 billion in financing activities. He gained his designation at PricewaterhouseCoopers, where he worked as a manager in the assurance practice.

Greg Bell is Project Manager for Reflex Advanced Materials. He is a multi-disciplined engineering management professional with more than 40 years of experience in the natural resources sector. Mr. Bell has successfully built and managed several start-up operations in various capacities. He has been active in graphite and lithium exploration for the past seven years.

Christopher W. Hill leads the company’s Corporate Development initiatives. He is an investor and entrepreneur with over a decade of experience in the capital markets. Mr. Hill began his career as an investment advisor and then began to consult and advise private companies on their paths to becoming publicly traded. He specializes in corporate development and strategic financing utilizing his large network in the capital markets.

Reflex Advanced Materials Corp. (RFLXF), closed Sunday's trading session at $0.095079, up 31.871%, on 2,051 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.063/$0.72.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Scientists at Purdue University are trying to develop a new treatment for glioblastoma tumors. Glioblastoma is a type of cancer that originates in the spinal cord and/or brain. This cancer is fatal, with a median time of survival of 14 months. Conventional treatments for other cancers, including immunotherapy and chemotherapy, are ineffective on this particular cancer. These treatments work by blood cells being taken from a patient then reintroduced back into their bodies after genetic engineering to fight cancer cells. Other researchers involved include Xue Yao, Kyle B. Lupo, Jiao Wang, Shambhavi Borde, Bennett D. Elzey, Sandra Torregrosa-Allen, Nadia A. Lanman, Sagar Utturkar and MacKenzie McIntosh. The efforts being put into researching new brain cancer treatments along with the work of companies such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) could soon yield alternatives that offer patients better clinical outcomes and an improved quality of life despite having a diagnosis of these hard-to-treat cancers.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Sunday's trading session at $0.215, up 5.3922%, on 109,097 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.19/$2.98.

Recent News

Software Effective Solutions Corp. (OTC: SFWJ)

The QualityStocks Daily Newsletter would like to spotlight Software Effective Solutions Corp. (OTC: SFWJ).

New surveys show that more than 10 years after voters in Colorado passed a ballot initiative making it the first state in America to legalize adult-use cannabis sales, voters don't regret their decision. Results from one poll conducted by the Colorado Polling Institute show that about 67% of registered voters saw the reform as a positive change for Colorado. This poll's results were published in March.

A separate poll carried out by Public Policy Polling (PPP) between April 8–9, 2024, determined that more than 71% of voters in the state thought marijuana needed to be legal and regulated in a way similar to alcohol. The survey polled 698 registered voters, with 70% of those polled noting that marijuana regulations didn't need to be more restrictive than regulations on alcohol. A report released by Colorado's Legislative Council Staff shows that the state generated more tax revenue from marijuana than cigarettes and alcohol during the previous fiscal year. The growing support for marijuana legalization even in states that have already passed laws ending prohibition is testament to the fact that as licensed companies such as Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) are allowed to operate, benefits such as job creation of the cannabis industry spread out to nearly every sphere of life in those communities.

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) is a global infrastructure and holding company in the cannabis industry. MedCana currently has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of holdings.

MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world.

MedCana’s goal is to be the world’s premier resource for pharmaceutical cannabis products. The company believes its advantage is its global view and reach. From initial cultivation to final product, MedCana aims to help partners produce pharmaceutical CBD and other extracts that will have no equal.

The company’s mission is to utilize its technology to partner with and develop companies that provide premium pharmaceutical-grade cannabis extracts with absolute integrity, sustainability and social responsibility. MedCana’s team of pharmaceutical scientists includes some of the most respected chemists in the world. They aim to ensure that the company’s customers and partners create premium cannabis extracts that meet the growing worldwide demand. MedCana’s software is designed to ensure traceability and quality from seed to finished product.

MedCana is headquartered in Austin, Texas, with offices in Colombia.


MedCana announced in May 2023 the beginning of full-scale production of non-THC cannabis for export to Europe in response to high demand in that market. This expansion comes after the successful completion of full crop cycle testing and infrastructure development at production sites in Columbia.

The recent acquisition of the assets of Tokan Corp., a software company focused on creating an enterprise resource planning (ERP) platform for the cannabis industry, and Eko2O S.A.S., a greenhouse and irrigation engineering company, has positioned MedCana for explosive growth in the region.

As a MedCana subsidiary, Eko2O SA will increase the company’s revenue potential in Central and South America. The subsidiary specializes in the construction and distribution of greenhouses and sophisticated irrigation platforms. A positive outlook has resulted from the company’s expansion as it investigates new opportunities for greenhouse and irrigation system installations in Panama and Uruguay. These opportunities are expected to accelerate Eko2O’s development and strengthen its position as a top supplier of innovative agricultural solutions in cannabis and other sectors that are quickly moving to high technology agricultural production.

In addition, MedCana has started talks with the government in Argentina about possible incentives for beginning operations in that country as part of its ongoing worldwide development strategy. Support from the Argentinean government and the start of new operations there would greatly increase MedCana’s market share in Latin America and solidify the company’s position as the market leader in the cannabis industry.

Market Opportunity

According to a report by Grand View Research, a San Francisco-based market research and consulting company, the global cannabis extract market was valued at $3.5 billion in 2022 and is expected to expand at a CAGR of 20% from 2023 to 2030 to be worth more than $15 billion.

Growing demand for cannabis extracts, including oils and tinctures, and the increased legalization of marijuana for the treatment of different chronic ailments like arthritis, Alzheimer’s, anxiety and cancer are driving the expansion of the industry. The marijuana derivative industry is flourishing due to a greater understanding of its various medical benefits.

Management Team

Jose Gabriel Diaz is CEO of MedCana. He has successfully built, grown and sold multiple telecom companies. He was senior vice president of sales at IP Communications, a national high-speed data provider. He also founded Reallinx, a national data carrier later sold to GTT Communications. Additionally, he is currently president of the A.E.M. Business and Entrepreneurship Association in Austin, Texas.

Claudio Jiménez Cartagena, QF, Ph.D. is Chief Scientific Officer at MedCana. He joined MedCana after working with Sosteli Pharma as Technical Director and serving as a director consultant for the Corporation for Agricultural Industrial Development at the University of Antioquia in Colombia. Before that, he worked as the scientific director at the Institute of Food Science & Technology. He holds a bachelor’s degree in pharmaceutical chemistry, a master’s degree in basic biomedical sciences and a doctoral degree in Environmental Engineering from the University of Antioquia.

Julián Alberto Londoño Londoño, Ph.D., is Senior Vice President of Operations at MedCana. He previously served as general manager for the Corporation for Agricultural Industrial Development, and as Chief Scientific Officer at Sosteli Pharma in the Resource Management Department. He has developed multiple U.S. patents, and recently served as senior advisor to the Secretariat of Agriculture Development for the Government of Antioquia. He holds a doctorate in Chemical Sciences from the University of Antioquia.

Software Effective Solutions Corp. (OTC: SFWJ), closed Sunday's trading session at $0.055, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.000001/$0.09.

Recent News

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF)

The QualityStocks Daily Newsletter would like to spotlight First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) .

While some have claimed that the green-energy transition could have a negative impact on American employment, the nascent renewable energy sector actually has the potential to provide plenty of employment opportunities for Gen Z. A recently launched initiative called the American Climate Corps is already providing young Americans with hundreds of employment opportunities in the emerging green sector. Inaugurated by the Biden administration in September 2023, the program will pay hundreds of Gen Z'ers in the country to help develop climate solutions across the country. The program will eventually facilitate the installation of more than 20,000 people in internships, fellowships and jobs that will put them on the path to joining the green-energy workforce. Modeled on the Civilian Conservation Corps formed by President Franklin D. Roosevelt, the Climate Corps will offer young Americans opportunities in clean energy and other sectors such as urban areas, food systems, public lands and waters, and capacity building. Representative Alexandria Ocasio-Cortez said at the Earth Day event that the young people who join the American Climate Corps will play a role in the climate change fight, help build a "just economy," and develop into "profoundly influential leaders" in the United States. The green jobs envisioned will materialize sooner if green-energy metal extractors such as First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) obtain sufficient supplies of metals onto the market and those are used to generate and store the clean energy needed to address the energy needs of the world.

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) is committed to exploring for and providing essential and critical metals, including tellurium, gold, silver, copper and tungsten, for North American markets. This objective is anchored by the company’s Deer Horn tellurium-gold-silver-copper project in British Columbia, Canada, and further enhanced by its property option on the Klondike tellurium-gold prospect located in Colorado, USA.

First Tellurium’s unique business model is to generate revenue and value through mineral discovery, project development, project generation and cooperative access to untapped mineral regions in indigenous territory with sustainable exploration potential.

The company is headquartered in Vancouver, British Columbia.

Tellurium and the Green Energy Revolution

Tellurium has a key role to play in the ongoing green energy revolution. It is widely used in the manufacturing of photovoltaic cells for solar panels.

Despite this utility, ongoing trade tensions between China and the U.S. create implications for both tellurium and the production of cadmium-tellurium solar cells. Earlier this year, China announced plans to restrict exports of critical metals gallium and germanium, both essential for the production of semiconductors. For reference, China produces around 80% of the world’s gallium and approximately 60% of the world’s germanium.

China’s recent trade restrictions amplify the fragility of the North American tellurium supply, as the Asian nation currently produces about 60% of the world’s tellurium. This sustained supply vulnerability is why First Solar, the United States’ largest solar panel producer, set up a worldwide search for tellurium deposits in the mid-2000s.

“In North America alone, our understanding is that First Solar looked at over a hundred tellurium properties,” First Tellurium CEO Tyrone Docherty stated in a news release. “Their number one property by far, which they acquired, was the Colorado Klondike which we now control.”

The U.S. is now looking to secure safe, domestic sources of tellurium and many other critical metals to pre-empt potential shortages. The Biden administration has instituted a stream of policies, particularly the U.S. Inflation Reduction Act, to source solar components from North America and other “friendly” jurisdictions.

As the only junior mining company in the world focused on tellurium exploration, First Tellurium is ahead of the curve in capitalizing on these initiatives to establish strategic, domestic supplies of key resources for solar panel manufacturers.

First Tellurium’s ESG Initiatives

Through its exploration and partnerships with Fenix Advanced Materials, Cheona Metals and IRMA, First Tellurium strives to generate a measurable, beneficial social or environmental impact alongside a financial return. The company conducts a diversified search for metals, working in alliance with indigenous peoples, NGOs, governments and leading metals buyers. First Tellurium believes this is the future of mineral exploration — generating revenue by exploring responsibly and leveraging diverse partnerships.

First Tellurium proudly adheres to, and supports, the principles and rights set out in the United Nations Declaration on the Rights of Indigenous Peoples and, in particular, the fundamental proposition of free, prior and informed consent.



Deer Horn Tellurium-Gold-Silver-Copper Project

Deer Horn is located on 51.33 square kilometers (km) in west-central British Columbia, 36 km south of the prolific Huckleberry copper-molybdenum mine and 135 km southwest of the community of Burns Lake. It is one of few significant tellurium discoveries outside Asia and includes a 2.4 km-long vein system of high-grade gold, silver and tellurium, as well as broader zones of bulk-tonnage gold, silver and tellurium mineralization. The company completed a positive Preliminary Economic Estimate and has begun permitting for a 10,000-tonne bulk sample program to advance the project toward mine feasibility. It is North America’s only silver-gold-tellurium property with an NI 43-101 compliant tellurium resource, and it hosts a number of other mineralized targets and zone containing critical metals such as copper, tungsten and zinc.

First Tellurium owns 50% of the property, with an option to acquire up to a 75% interest. The company has engaged Dias Geophysical of Saskatoon, Saskatchewan, to conduct induced polarization (IP) geophysics on the Deer Horn Project in summer 2023. The program is designed to help develop drill targets for a subsequent drilling program.

Klondike Gold-Tellurium Project

The Klondike property is located in Saguache County, Colorado, southwest of Buena Vista in the state’s historical mining district. The company reports it has engaged Burgex Mining Consultants of Sandy, Utah, to stake additional claims around the Klondike property. The claims have been filed with the Bureau of Land Management.

Klondike demonstrates exceptional tellurium grades. Tellurium, used in high-efficiency cadmium telluride (Cd-Te) solar panels, next-generation lithium-ion batteries and thermoelectric devices to change heat into energy, is an essential element for the world’s transition to green energy.

The Klondike property was a top tellurium prospect owned previously by First Solar Inc., one of the world’s largest solar panel producers. First Solar terminated its worldwide raw materials exploration program in 2012 and sold the property to Colorado Klondike LLC, which optioned the project to First Tellurium. Colorado Klondike, led by First Solar’s former Exploration Manager in North America, is managing the upcoming exploration program.

The Colorado Geological Survey (CGS), in partnership with the Colorado School of Mines, reported on First Solar’s exploration at Klondike in 2015, noting: “Surface sampling by First Solar, Inc. in 2006 found very high tellurium grades of up to 3.3% (33,000 ppm), along with locally high gold grades. Tellurium grades at Klondike were the highest encountered in the company’s nationwide exploration program.”

Market Outlook

First Tellurium in spring 2023 referenced recent forecasts by the International Energy Agency (IEA) pointing to rapid growth in solar photovoltaic (solar PV) deployment worldwide. According to the agency, solar PV installations will generate more power by 2027 than any other energy source, including coal, natural gas and hydro. To meet this demand, consumption of both silver and tellurium, key components of solar panels, is expected to surge in coming years.

Chen Lin, founder of Lin Asset Management, has written in his investment newsletter for clients that solar PV is now the largest industrial usage of silver. He said that in 2022 solar PV production used about 12% of total silver demand, or about 120 million ounces of silver. Lin expects this number to rise dramatically in the coming years, and that is likely to lead to silver supply deficits for decades to come.

Lin points out that solar power is now the cheapest source of energy in many parts of the world and that all forecasts point to dramatic expansion of solar PV in the coming two decades. Conservative estimates forecast 300 gigawatts of solar PV production by 2027, up from the current level of about 200 gigawatts.

Management Team

Tyrone Docherty is President, Director and CEO of First Tellurium Corp. He previously served as President and CEO of Quinto Mining Inc., taking over when it had a market cap of $4 million. With limited resources in a difficult market environment, he raised more than $30 million and advanced Quinto’s Quebec iron ore property to a viable project. Quinto later sold for $175 million, with Quinto management taking shares of the purchaser, Consolidated Thompson Iron Mines, amounting to approximately 20-21% of that company. Consolidated Thompson Iron Mines sold two years later for $4.9 billion, giving the former Quinto team an enterprise value of approximately $1 billion. From 2012 to 2018, Mr. Docherty was Director and Chairman of Mason Graphite Inc. He has worked in the financial and minerals markets for more than 30 years.

Tony Fogarassy, M.Sc. LL.M., is Chairman of First Tellurium Corp. He is a lawyer and a geologist. His extensive legal and technical expertise includes minerals, oil and gas, coal and renewable energy projects and environmental and aboriginal/indigenous law in North America, Africa and Asia. He graduated as gold medalist in geological sciences from the University of British Columbia and in law from the London School of Economics.

First Tellurium Corp. (OTCQB: FSTTF), closed Sunday's trading session at $0.0576, off by 6.9467%, on 3,500 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.047785/$0.134.

Recent News

Longeveron Inc. (NASDAQ: LGVN)

The QualityStocks Daily Newsletter would like to spotlight Longeveron Inc. (NASDAQ: LGVN) .

Longeveron (NASDAQ: LGVN), a clinical-stage, biotechnology company developing regenerative medicines, will be presenting at next month's Planet MicroCap Showcase. The conference is slated for May 1–2, 2024, in Las Vegas. According to the announcement, Longeveron's presentation is scheduled to begin at 4:30 p.m. PT. An archived copy of the webcast will be available on the company's website following the presentation. In addition, Longeveron officials will be available for one-on-one investor meetings.

To view the presentation, visit

To view the full press release, visit

Longeveron Inc. (NASDAQ: LGVN) is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. The Company’s research and therapies are aimed at improving the outcome of infants born with a life-threatening heart condition, as well as improving the healthspan for the aging population – the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging, with function and ability to perform activities of daily living.

Longeveron is involved in clinical trials in the following indications: Hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty.

The Company’s philosophy revolves around the idea that regenerative medicine may hold the potential to improve certain rare medical conditions and contribute to healthy aging. While there has been a remarkable rise in life expectancy over the last century due to medical and public health advancements, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging.

Longeveron’s lead investigational product is Lomecel-B™, an allogeneic Medicinal Signaling Cell therapy product isolated from the bone marrow of young, healthy adult donors. As humans age, they experience a decrease in immune system function, a decline in blood vessel functioning, chronic inflammation, and other issues. Clinical data has suggested that Lomecel-B™ may address these conditions through multiple mechanisms of action (MOA) that simultaneously target key aging-related processes.

The Company is headquartered in Miami, Florida.


Lomecel-B™ is being evaluated in multiple clinical trials for aging-related chronic diseases and other life-threatening conditions under U.S. FDA-approved Investigational New Drug applications. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas.

The drug is made from special living cells called Medicinal Signaling Cells (MSCs) that are isolated from fresh bone marrow tissue that has been donated by adult donors aged 18 to 45. Once the MSCs have been isolated from the fresh bone marrow through a careful selection process, the cells are culture-expanded (allowed to replicate under controlled laboratory conditions) into the billions using specialized techniques and processes. After a specific number of expansion cycles, called “passages,” the cells are harvested, separated into specific doses (e.g., 50 million cells), and cryopreserved until future use.

These cells have been shown to have characteristics that allow them to be transplanted from a donor to host without triggering a harmful immune response in the recipient, and they can be administered on an outpatient basis in as little as 40 minutes after thawing. Because of these characteristics, Lomecel-B™ is considered an “off-the-shelf” product.

In some trials, such as for Alzheimer’s disease and Aging-related Frailty, Lomecel-B™ is administered via peripheral intravenous infusion, while, in the Company’s HLHS trial, Lomecel-B™ is administered via direct injection into the heart tissue.

Market Opportunity

Longeveron estimates the potential market size for Lomecel-B™ in the treatment of HLHS to be up to $1 billion annually, globally.

U.S. patients suffering from Aging-related Frailty are estimated using U.S. Census Bureau statistics to be approximately 8.1 million. That population potentially represents a market for Lomecel-B™ of between $4 billion and $8 billion globally per year, according to Company estimates.

Additionally, the Alzheimer’s Association puts the number of Americans with that disease at 5.1 million, highlighting another potentially addressable market for Lomecel-B™, that’s worth $5 billion to $10 billion annually.

Management Team

Wa’el Hashad is CEO of Longeveron. He has more than 35 years of experience in the pharmaceutical and biotech industries. He has launched several successful brands in the U.S. and worldwide markets. Prior to joining Longeveron, he was president and CEO of Avanir Pharmaceuticals. Before Avanir, he was the chief commercial officer of Seres Therapeutics. He also has held senior leadership positions at Amgen, Boehringer Ingelheim, and Eli Lilly and Company. He holds a bachelor’s degree in pharmacy from Cairo University and an MBA from the University of Akron.

Joshua M. Hare, M.D., FACC, FAHA, is Co-Founder, Chief Science Officer and Chairman of Longeveron. He is a double board-certified cardiologist and is the founding director of the Interdisciplinary Stem Cell Institute at the University of Miami’s Miller School of Medicine. He is a recipient of the Paul Beeson Physician Faculty Scholar in Aging Research Award and is an elected member of the American Association of Physicians and The American Society for Clinical Investigation. He is also an elected Fellow of the American Heart Association. He received a bachelor’s degree from the University of Pennsylvania and his M.D. from The Johns Hopkins University School of Medicine.

Lisa Locklear is CFO at Longeveron. She previously served as the senior vice president and CFO for Avanir Pharmaceuticals. Prior to Avanir, she held senior financial roles at GSN Games, CoreLogic, Ingram Micro, the Walt Disney Company, and Price Waterhouse, with assignments in Paris and London. She holds a bachelor’s degree in plant science from the University of California, Davis, and an MBA from the University of California, Irvine. She is a licensed CPA (inactive) and is a member of the American Institute of Certified Public Accountants, the California Society of CPAs, and Financial Executives International.

Dr. Nataliya Agafonova, M.D., is the Chief Medical Officer at Longeveron. She previously served as clinical development lead, senior medical director, and product development chair at Otsuka Pharmaceuticals. Before that, she was the clinical development lead and senior medical director at Bristol-Myers Squibb. She previously held senior leadership positions at Ardea Bioscience, Biogen, Amgen, and Genzyme Corporation. She earned an M.D. from the Ukrainian National Medical University and completed her internal medicine residency at Kharkov State University Hospital in Ukraine.

Certain statements in this corporate profile that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, statements regarding the offer and sale of securities, the terms of the offering, about the ability of Longeveron’s clinical trials to demonstrate safety and efficacy of the Company’s product candidates, and other positive results; the timing and focus of the Company’s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the Company’s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the Company’s product candidates; the Company’s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the Company’s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the Company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the Company’s ability to attract and retain such personnel; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; the Company’s financial performance and ability to continue as a going concern, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Additionally, Longeveron makes no assurance that any public offering of its securities as described herein will occur on the timelines, in the manner or on the terms anticipated due to numerous factors. Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 14, 2023 and its Quarterly Report on Form 10-Q for the second quarter of 2023 filed with the SEC on August 11, 2023. The forward-looking statements contained in this corporate profile are made as of the date of this corporate profile, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Contact
Mike Moyer
LifeSci Advisors
Tel: 617-308-4306

Date prepared: August 31, 2023

Longeveron Inc. (NASDAQ: LGVN), closed Sunday's trading session at $1.75, up 4.7904%, on 373,405 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.60/$44.00.

Recent News

PaxMedica Inc. (NASDAQ: PXMD)

The QualityStocks Daily Newsletter would like to spotlight PaxMedica Inc. (NASDAQ: PXMD).

PaxMedica (NASDAQ: PXMD), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, was featured in the latest episode of The Bell2Bell Podcast as part of IBN's sustained effort to provide specialized content distribution via widespread syndication channels. Howard Weisman, CEO of PaxMedica, and Dr. Marshal Lemerani, Program Manager at the Malawi Ministry of Health, joined the program to discuss the urgent request for medical assistance from Malawi and PaxMedica's swift response. The podcast shed light on PaxMedica's commitment to addressing the critical shortage of medications required to combat the life-threatening sleeping sickness crisis in Malawi, with Weisman highlighting the pressing need for IV suramin (PAX-101), a crucial medication in treating Trypanosoma brucei rhodesiense Human African trypanosomiasis ("TBr HAT"), and PaxMedica's immediate action plan to aid. Lemerani shared insights into the challenges faced by healthcare professionals in Malawi and expressed gratitude for PaxMedica's support in this dire situation.

To view the full press release, visit

PaxMedica Inc. (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (APTs) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms.

The company’s lead programs are focused on ASD, for which there are currently no approved pharmacologic treatments that target its cause and symptoms. Currently used treatments only address the symptoms of the condition, rather than targeting the pathophysiology itself.

PaxMedica is on a promising path to address these unmet medical needs, bringing hope to millions. Anti-purinergic therapies target the excess production of purines in cells. An overexpression of purines can offset homeostasis and result in an overproduction of cellular adenosine triphosphate, the main energy molecule in all living cells.

The company is headquartered in Tarrytown, New York.

Product Pipeline

PaxMedica is building a robust pipeline of products targeting ASD and related neurodevelopmental conditions. The company’s lead product in development may help eliminate, reduce or modulate some of the more troublesome aspects of ASD. That would open the potential for people with autism to integrate their behavior with others more successfully and improve their lives.

PaxMedica’s lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting anti-purinergic therapy that has been known for over 100 years. Its current pipeline includes:

  • PAX-101 (IV Suramin) for ASD – PAX-101 completed a Phase 2B study for ASD in 2021. Suramin is a broadly acting APT and has reported positive results from a dose range study. The results of PaxMedica’s Phase 2B study, which targeted 52 subjects across six sites in South Africa, were presented to AACAP in October 2021.
  • PAX-102 (Intranasal Suramin) – PaxMedica has developed a proprietary intranasal formulation of suramin that is currently being evaluated in ASD and other neurodevelopmental conditions.
  • PAX-101 for HAT – Given suramin’s historical use as a treatment for Human African Trypanosomiasis (HAT), or African Sleeping Sickness, the company is also developing PAX-101 as a treatment for HAT. PaxMedica’s most advanced program is the pursuit of PAX-101 for early-stage East African HAT.
  • Selective APTs – PaxMedica has conducted several preclinical studies to evaluate other APTs that are more selective to specific purinergic receptors and may offer additional benefits over suramin.

Market Opportunity

According to a report by Fortune Business Insights, a leading global market research company, the global ASD therapeutics market was estimated at $1.93 billion in 2022 and is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, a CAGR of 7.9% over the forecast period. As there is no current treatment for the core symptoms of autism, PaxMedica believes the addressable market for PAX-101, if approved, could greatly exceed these forecasts.

Autistic disorder, Asperger’s Syndrome and Pervasive Development Disorder are the three main types of ASD, affecting millions of people globally. A 2020 report by the U.S. Centers for Disease Control & Prevention estimated that one in 36 children in the U.S. have been diagnosed with autism disorder.

Several factors are expected to contribute to market growth prospects. A growing prevalence of the condition globally and rising awareness coupled with available treatment options are key factors expected to drive ASD therapeutics market growth during the forecast period. Growing investment in R&D to find effective treatments is also expected to fuel global market growth.

Management Team

Howard Weisman is Chairman and CEO of PaxMedica. He has been a founder and CEO of several specialty pharma and medical device companies. Most recently, he was executive chairman and co-founder of Sofregen, a biotech company. He also served as CEO and president of Seventh Sense Biosystems, a medical device development company. He also was founder, chairman and CEO of EKR Therapeutics, a specialty pharmaceutical company, and founder and COO of ESP Pharma, a company focused on cardio and neurovascular products. He has a bachelor’s degree in chemistry from Rutgers University.

David Hough, M.D., is Chief Medical Officer at PaxMedica. He is a neuroscience clinical development consultant who previously served as vice president at Janssen Research and Development and in various leadership roles over 17 years. Most recently, he was the compound development team leader for SPRAVATO® for treatment-resistant depression. Prior to that, he was the schizophrenia disease area leader. He played a pivotal role in the development programs for oral INVEGA®, INVEGA SUSTENNA® and XEPLION® for schizophrenia. He is a graduate of West Point and is board certified in psychiatry.

Stephen Sheldon is COO and CFO at PaxMedica. He has served as CEO of Thailand-based specialty healthcare company Indochina Healthcare Co. Ltd. since 2015. Previously, he was a consultant for PricewaterhouseCoopers Healthcare Advisory in the Chicago office. He was responsible for developing specialty pharmacy patient programs, strategy development for specialty products and compliance programs. He has an MBA from Thunderbird School of Global Management and a bachelor’s degree in computer science and visual arts from Bowdoin College.

PaxMedica Inc. (NASDAQ: PXMD), closed Sunday's trading session at $0.7398, up 5.0554%, on 499,734 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.372/$29.75.

Recent News

HealthLynked Corp. (OTCQB: HLYK)

The QualityStocks Daily Newsletter would like to spotlightFathom HealthLynked Corp. (OTCQB: HLYK) .

HealthLynked Corp. (OTCQB: HLYK) is at the forefront of a transformative movement in healthcare, utilizing its extensive collection of health data to improve care for all. With a commitment to leveraging its advanced technology platforms, HealthLynked employs a sophisticated, cloud-based network that serves as a comprehensive repository for personal health data. This system not only simplifies the management and archiving of medical records but also enables the application of AI to deliver personalized healthcare insights. Through deep analysis of this data, HealthLynked’s AI capabilities help identify the root causes of diseases, tailor healthcare solutions to individual needs, and accelerate medical discoveries.

HealthLynked Corp. App

In addition to these capabilities, HealthLynked provides a user-friendly platform for booking healthcare appointments, similar to how OpenTable operates for restaurant reservations. This feature allows patients to conveniently book appointments with healthcare providers across the country, including options for telemedicine consultations, enhancing accessibility and efficiency in healthcare service delivery.

Strategically headquartered in Naples, Florida, HealthLynked operates through three primary divisions: Health Services, Digital Healthcare, and Medical Distribution. Each division supports the company’s mission to revolutionize patient care and health management. Positioned as a potential leader in healthcare AI, HealthLynked is dedicated to shaping the future of the industry over the next 20 years, driving significant advancements in healthcare accessibility and effectiveness through innovation and technology.

HealthLynked Corp. Reach

Strategic Initiatives and Operational Highlights

The company’s commitment to enhancing global health is evident in its dual goals: transforming healthcare through advanced technology and creating a patient-centric network that accelerates medical discoveries and the development of disease cures.

HealthLynked’s intellectual property portfolio is robust and strategically developed to enhance healthcare delivery and management. In March 2023, HealthLynked was granted a patent for a groundbreaking healthcare-specific wireless access point, known as the “Patient Access Hub.” This technology significantly improves the efficiency of healthcare practices by enabling real-time monitoring of patient flow within facilities. It intelligently determines patients waiting in exam rooms and calculates wait times, alongside other critical practice metrics. This system not only enhances patient experience by reducing unnecessary wait times but also optimizes resource allocation within healthcare settings.

Additionally, in October 2023, HealthLynked filed a patent application for its advanced AI program, ARI (Augmented Real-time Interface). ARI acts as a virtual doctor for patients, capable of performing medical intake, booking appointments, and providing personalized medical recommendations based on a patient’s medical history. By integrating these tasks, ARI streamlines the healthcare process, reducing the administrative burden on healthcare providers and ensuring that patients receive timely and tailored healthcare advice. This AI-driven interface enhances the accessibility and personalization of healthcare, embodying HealthLynked’s commitment to leveraging technology for better health outcomes. The company recently launched HealthLynked 3.2.0, an advanced version of its application, incorporating telemedicine, AI-driven personal healthcare guidance, and remote patient monitoring – setting a new standard in healthcare technology.

Market Position and Future Outlook

According to Facts and Figures Research, a research and consulting firm, the global market for patient-centric healthcare applications is projected to reach $41.6 billion by 2030, growing at a CAGR of 18.77% from 2022. HealthLynked’s offerings align perfectly with this expansive market opportunity, especially with increasing demands for digital health solutions and data management in healthcare.

HealthLynked’s strategic direction, spearheaded by its seasoned management team, is designed to leverage these market dynamics, enhancing patient engagement and healthcare efficiency on a global scale.

Management Team

Michael T. Dent, M.D., Founder, CEO, and Chairman, brings extensive experience from his foundational role at NeoGenomics and leadership in various healthcare and technology sector companies.

David Rosal, CFO, with previous senior roles at Teradata and McDonald’s Corporation, brings a wealth of expertise in financial and business integration strategies essential for growth and operational efficiency.

Chris Hall, CTO, with a strong background in global technology development from his time at Siemens and several patents to his name, is instrumental in driving the innovation and technological advancement at HealthLynked.

Bill Crupi, Operations Manager, has a proven track record in streamlining operations and enhancing productivity across multiple sectors within the healthcare industry. His expertise is crucial in maintaining the operational excellence that HealthLynked is known for.

Michael Paisan, Director of Investor Relations, leverages his extensive experience in finance and communications to enhance HealthLynked’s relationships with investors and stakeholders, ensuring transparent and effective communication of the company’s value and growth strategy.

Gagan Babber, Manager of Software Development, oversees the HealthLynked development teams based in the U.S. and India. With a robust background in engineering and software development, he plays a critical role in guiding the technological direction of HealthLynked’s products. His expertise in developing scalable, innovative software solutions is essential for driving the company’s technical initiatives forward and ensuring that HealthLynked stays at the forefront of digital healthcare technology.

HealthLynked Corp. (OTCQB: HLYK), closed Sunday's trading session at $0.05378, off by 2.7486%, on 51,696 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.033/$0.1039.

Recent News

Fintech Ecosystem Development Corp. (NASDAQ: FEXD)

The QualityStocks Daily Newsletter would like to spotlight Progressive Care Inc. (OTCQB: FEXD).

Fintech Ecosystem Development Corp. (NASDAQ: FEXD) is a special purpose acquisition company (SPAC) formed for the purpose of effecting one or more business combinations with an intent to focus on the financial technology sector.

The company’s mission is to create and grow a global financial services ecosystem to address unmet mobile money needs in developing and industrialized countries and markets. FEXD plans to achieve this by acquiring and merging with financial technology pioneers that have the potential to help establish its global fintech ecosystem, and by continuing the development of proprietary technologies and applications to keep the company at the forefront of the cashless society market.

Digital money is replacing physical cash. Consumers can buy products and services from anywhere in the world and make payments across borders. Parents can send money to students studying in other countries. Migrant workers are sending money to families in developing nations. Rural villagers without banks can send and receive money using their smartphones. FEXD is developing mobile transaction platforms, applications and services that are helping to implement these changes.

The company plans to offer a diverse portfolio of products and services to consumers and businesses in the United States, South Asia, East Asia, Africa, Europe and Latin America. Its growth strategy includes acquisition, innovation and market development.

FEXD is a Delaware corporation based in Collegeville, Pennsylvania. The company was launched in May 2021 by a management team led by Dr. Saiful Khandaker that has extensive experience in developing and managing financial service platforms and applications, primarily in the mobile money sector. FEXD is sponsored by Revofast LLC.

Acquisition Targets

In September 2022, FEXD announced definitive agreements for business combinations with Rana Financial Inc., a Georgia corporation, and Mobitech International LLC (dba Afinoz), a limited liability company organized in the United Arab Emirates. The agreements call for Rana and Afinoz to become wholly owned subsidiaries of FEXD, with the combined company expected to continue trading on the Nasdaq under existing ticker symbol ‘FEXD’. The mergers are expected to close in Q2 2023.

Rana Financial

Rana Financial is a licensed money transfer company founded in 2009. Rana provides fast and affordable online and mobile transfer of funds between the U.S. and Latin America. Rana has been providing money transfer services in the U.S. market for 13 years and has 30,000 active users. Rana’s money transfer business grew to 200,000 transactions in 2021. The merger agreement values Rana at an implied $78 million enterprise value.

Mobitech International LLC

Mobitech International LLC (dba Afinoz) is an artificial intelligence-enabled digital lending platform used by India’s leading banks, non-banking financial companies and fintech loan providers. Afinoz’s fintech platform supports enterprises making loans primarily to middle- and working-class borrowers via its website or through its mobile phone application. Afinoz’s platform makes loans available and affordable to millions of Indian workers and unbanked users by providing access at a low cost. Afinoz’s platform has more than 50 lending partners, and its database of registered users in India includes more than two million individuals. The merger agreement values Afinoz at an implied $120 million enterprise value.

Market Opportunity

According to analysis by global market research firm Mordor Intelligence, the worldwide financial technology market is valued at approximately $194 billion in 2023 and is projected to grow to nearly $500 billion by 2028, representing a CAGR of 18.97% for the forecast period. According to the report, various financial crises and the COVID-19 pandemic have fueled consumer adoption of, and investor interest in, fintech over the past several years.

Management Team

Dr. Saiful Khandaker is Founder, CEO and President of FEXD. He is Group CEO and founder of FAMA Holdings Inc., a global developer of fintech platforms, applications and services based in the U.S. with offices in the U.K., India, Bangladesh and Zambia. He is currently leading the development of the FAMACASH™ network, a global fintech ecosystem to provide fast, affordable mobile money services in underserved countries such as Bangladesh. Before founding FAMA, Dr. Khandaker spent more than two decades leading the development of software solutions for Fortune 100 companies and startups. He also helped numerous clients modernize their fintech services as Chief Technology Officer at Mi3. He holds a Doctor of Management in Organizational Leadership, a Master of Science in Technology Management, and a Bachelor of Science in Computer Information Systems.

Jenny Junkeer is CFO at FEXD. She is a Chartered Accountant with over 17 years of experience. As CEO of Junkeer New Era Consulting, she leads a team specializing in helping companies launch and optimize business operations in fast-changing industries. She has extensive experience helping organizations scale operations to maximize value. She is an Adjunct Association Professor at Deakin University in Australia, a board member of the Global Health Initiative Foundation, and Director of Implementation at ConnectCV. She holds a Bachelor of Commerce Degree (Honors) from Monash University.

FingerMotion Inc. (FEXD), closed Sunday's trading session at $11.4, up 1.6043%, on 1,248 volume. The average volume for the last 3 months is 13,772 and the stock's 52-week low/high is $10.50/$11.54.

Recent News

Starco Brands Inc. (OTCQB: STCB)

The QualityStocks Daily Newsletter would like to spotlight Starco Brands Inc. (OTCQB: STCB).

Starco Brands Inc. (OTCQB: STCB) is a modern-day invention factory. The company’s unwavering mission is to invent and acquire consumer products and brands with behavior-changing technologies that spark excitement in the everyday.

This consumer product company has grown from a few million dollars in revenue to a current run rate of approximately $67 million in annual revenue in one year.

The company has succeeded by identifying whitespaces in eight core consumer categories and then either: 1) leveraging its internal R&D capabilities and dedicated manufacturing network to invent new technologies and brands or 2) utilizing the management team’s extensive M&A experience to acquire brands that fill the industry void, delighting consumers and retailers alike.

Whether the brand is developed internally or acquired, the company employs a modern marketing playbook to ensure its brands are at the forefront of culture; garnering unprecedented media attention and engagement that supports a robust sales network.

Starco Brands’ core competencies are inventing technologies, acquiring companies, marketing, building trends, pushing awareness, penetrating media (social and otherwise) and executing cutting edge pull-through strategies with a roster of globally recognized celebrities, influencers and media and distribution partners.

A commitment to changing the way people approach everyday activities is innate in the company’s corporate DNA.

The company is based in Santa Monica, California.


Whereas other consumer products companies are content with evolution, Starco Brands has its mind set on creating a revolution across the industry. From disrupting the spirits industry with Whipshots, the world’s only vodka-infused whipped cream, to Soylent, the original food tech company, Starco Brands is putting the CPG world on notice. Its portfolio of brands includes:

  • Whipshots is a first-of-its-kind alcoholic whipped cream launched in 2021 with celebrity partner Cardi B. Consumers have embraced this boozy concoction, putting it on top of cocktails, coffees and desserts, or enjoying it straight from the can. In just over a year, the brand has sold over 2 MILLION cans, making it one of the fastest growing spirits in history.
  • Winona Pure gives consumers movie theatre popcorn in the comfort of their own homes. All the flavor and none of the additives is the story behind these all-natural, non-GMO popcorn seasoning sprays. A simple spray is all it takes to add the perfect pop of flavor to the classic theatre treat.
  • Art of Sport, co-founded by the great Kobe Bryant, is the number one body care brand for athletes. With a growing line of personal care products tested by the world’s greatest athletes, these daily skin essentials give consumers everything they need to feel fresh, stay protected and confident and perform at their peak every day.
  • Skylar is the first and only line of perfumes on the market that are hypoallergenic and safe for sensitive skin. With the strong support of industry titan Sephora, the brand has quickly attracted a loyal following.
  • Soylent is a technological feat. Originally funded by Google Ventures and Andreessen Horwitz, Soylent is dubbed as the world’s most perfect food. Made from sustainably grown plant-based ingredients, Soylent’s line of products is scientifically developed to provide all the functional ingredients, vitamins, minerals, fats, carbohydrates and protein that the body needs – all in convenient, delicious and affordable packages. Soylent’s innovative product line-up includes complete nutrition powders, ready-to-drink shakes, 100-calorie snack bars, high protein nutrition shakes and energy boosting nutrition shakes. Soylent was also the recipient of the 2023 Product of the Year Award by Kantar, a global leader in consumer research.

With award-winning marketing talent, Starco Brands develops robust, integrated marketing plans for every brand in its portfolio, ensuring an impactful presence across all verticals.

Market Outlook

Starco Brands’ varied brand portfolio gives it access to the growth of numerous product categories that are ripe for innovation.

Through its February 2023 acquisition of complete nutrition pioneer Soylent, Starco Brands is positioned to capitalize on the projected growth of the plant-based nutrition space. Research firm Statista valued the plant-based nutrition market at $29.4 billion in 2020 and forecasts its value at nearly $162 billion by 2030, representing a CAGR of 18.7% for the period.

Likewise, Starco Brands gained improved access to the global fragrance market through its December 2022 acquisition of Skylar. According to a report by Grand View Research, the global perfume market was valued at $50.85 billion in 2022 and is expected to grow to a value of nearly $80 billion by 2030, achieving a CAGR of 5.9% over the forecast period.

The company is primed to expand its access to other growth verticals as it advances on its path to invent and acquire behavior-changing technologies and brands.

Management Team

Ross Sklar is the CEO of Starco Brands. A chemical formulator by trade, he started his first company while still in college. Since 2004, he has made over a dozen acquisitions with multiple exits and controls an eclectic collection of industrial, household, personal care and food and beverage manufacturers covering many consumer-packaged goods categories.

Darin Brown is the Chief Operating Officer of Starco Brands. With over 20 years of experience in chemical manufacturing, business development, finance and mergers and acquisitions, he has scaled the company from the ground up. He oversees all internal operations for Starco Brands and is an integral liaison between the company and Mr. Sklar’s manufacturing facilities.

David Dreyer is Chief Marketing Officer of Starco Brands. With over 25 years of experience working with blue chip and startup brands, he oversees all marketing initiatives for the company. Mr. Dreyer comes to Starco having worked with such standout brands as Apple, Pepsi, Pizza Hut, Dr Pepper, Snapple, Infiniti, The GRAMMY’s, Honda and He is also a Professor of Advertising at USC’s Annenberg School for Communication.

Starco Brands Inc. (STCB), closed Sunday's trading session at $0.1289, up 0.742478%, on 998 volume. The average volume for the last 3 months is 64,141 and the stock's 52-week low/high is $0.10605/$0.20.

Recent News

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

469.304.9400 x 201

Sharing Services Global Corporation (SHRG), closed the day's trading session at $1.01, up 23.17%, on 276,351 volume with 217 trades. The average volume for the last 3 months is 279,074 and the stock's 52-week low/high is $0.27/$2.54.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.